Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability

Cambridge, England (ots/PRNewswire) - - Includes leading protein conjugation
technologies and industry brands Lightning-Link® and CaptSure(TM)

- Opportunity to combine Expedeon and Abcam's technologies to create new
products to support research and diagnostic development

Abcam plc, a global innovator in life science reagents and tools, is pleased to
announce the successful completion of the acquisition of Expedeon's Proteomics
and Immunology business, which includes Innova and TGR Biosciences, as of 1st
January 2020. Abcam and Expedeon are fully committed to providing continued
access to Expedeon's proteomics and immunology products and support so that the
life science community can perform their research and development without
interruption.

Dr John Baker, SVP Product Portfolio and Innovation, Abcam, commented:

"Our reputation as an innovator in the field of biological reagents, coupled
with our dedicated global commercialisation infrastructure, will allow us to
make these technologies readily available globally. We have had teams working on
conjugation for several years and the combination of this expertise with the
Expedeon portfolio and other complementary conjugation technologies, including
BrickBio's, provides a very powerful platform to enable us to deliver the
precision research tools required to address the majority of life science assays
used today and those emerging in the future."

Protein labelling is essential to biological research in proteomics and 84% of
researchers are looking for conjugation ready solutions[1]. Proteomics research
requires the use of molecular labels that are covalently attached to a protein
of interest to facilitate detection or purification of the protein or its
binding partners. With conjugation kits for over 50 types of labels for
applications across the life science industry, Expedeon technology supports a
diverse set of labels, including enzymes, metals, oligos, and fluorescent
proteins. Abcam will combine the newly acquired capture and conjugation
technologies with its extensive antibody and protein expertise to expand and
enhance its portfolio of off-the-shelf and custom reagents and tools.

Notes to Editors

[1] Abcam proprietary data.

About Abcam

As a global life sciences company, Abcam identifies, develops, and distributes
high-quality biological reagents and tools that are crucial to research, drug
discovery and diagnostics. Working across the industry, the Company supports
life scientists to achieve their mission, faster.

Abcam partners with life science organisations to co-create novel binders for
use in drug discovery, in vitro diagnostics and therapeutics, driven by the
Company's proprietary discovery platforms and world-leading, antibody expertise.

By constantly innovating its binders and assays, Abcam is helping advance the
global understanding of biology and causes of disease, which enables new
treatments and improved health. The Company's pioneering data-sharing approach
gives scientists increased confidence in their results by providing validation,
user comments and peer-reviewed citations for its extensive portfolio of over
100,000 products.

With ten sites globally, many of Abcam's 1,100 strong team are located in the
world's leading life science research hubs, complementing a global network of
services and support.

To discover more, please visit www.abcam.com and www.abcamplc.com.

Logo - https://mma.prnewswire.com/media/1061261/Abcam_Logo.jpg

Media Contacts

At Abcam:
Dr Lynne Trowbridge
T: +44 7815 167026
E: lynne.trowbridge@abcam.com

Additional content: https://www.presseportal.de/pm/140045/4484130
OTS: Abcam plc

Original-Content von: Abcam plc, übermittelt durch news aktuell